Acta Pharm. 70 (2020) 35-47

 

full paper

Original research paper

 

Antiproliferative evaluation of various aminoquinoline derivatives

TAO LIU, JING XU, YUNGANG WU, XIAOX LI, DETAO DING, DENGDIAN MA, MENGWEI YAO, WENZHONG WEI, WEI ZHANG, SHAOHUA WANG, JING YAO AND XIAOYU LI

lxyent@163.com; yjing_87@163.com

1 School of Clinical Medicine, Jining Medical University, Jining, Shandong, China

2 Affiliated Hospital of Jining Medical University, Jining, Shandong, China

3 School of Basic Medicine, Jining Medical University, Jining, Shandong, China

4 People’s Hospital of Hengshui, Hengshui Hebei, China

Accepted February 28, 2019

Published online May 16, 2019

 

Allergic rhinitis (AR) is a common disease that causes severe inflammation and even disabilities. Previous studies have reported baicalein to have an anti-inflammatory effect. However, the pharmacological action of baicalein on anaphylaxis has not been clarified yet. This study assessed the in vivo protective effect of baicalein post-treatment in an ameliorating ovalbumin (OVA)-sensitized AR rat model. Baicalein attenuated histological alterations, aberrant tissue repair and inflammation after OVA-induced AR. Baicalein reduced the frequency of nasal/ear rubs and sneezes in rats, and inhibited generation of several inflammatory cytokines (TNF-α, IL-1β, and IL-6) in both blood and nasal lavage of rats. Infiltrations of eosinophils, lymphocyte, and neutrophils were decreased in baicalein-administered rats. Furthermore, baicalein inhibited the expression of STAT3 phosphorylation in the nasal mucosa. In summary, baicalein attenuated OVA-induced AR and inflammation, which suggests it as a promising therapeutic agent for the alleviation of AR-associated inflammation and pathology.

 

Keywords: baicalein, ovalbumin, allergic rhinitis, inflammatory factors, p-STAT3